Helix BioMedix, Inc. (OTCPK: HXBM)
Health Care · Biotechnology · US
$1.75
+71.57% today · -50.0% 1Y
Helix BioMedix, Inc. (OTCPK: HXBM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $393.24K and employs 8 people.
Over the last twelve months the share price has lost 50.0%, trading between 1.00 and 4.50.
Tweenvest scores Helix BioMedix, Inc. across four factors: quality 28/100, value 44/100. Its strongest factor is value.
HXBM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $393.24K
- Revenue (TTM)
- $2.07M
- P/E
- —
- EPS
- -15.59
- Dividend yield
- —
- Beta (5Y)
- 1.37
- 52-week high
- $4.50
- 52-week low
- $1.00
- Avg volume (3M)
- —
- Shares outstanding
- 224.71K
- Employees
- 8
- Next earnings
- —
About Helix BioMedix, Inc.
Helix BioMedix, Inc. is a biopharmaceutical company, which focuses on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum. The company was founded in 1988 and is headquartered in Bothell, WA.
- ISIN
- US4232875074
- Founded
- 1988
- Listed since
- Mar 25, 1999
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.